1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort
- Contribution to journal › Article
-
Mark
Plasma p-tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic
- Contribution to journal › Article
- 2024
-
Mark
Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders
- Contribution to journal › Article
-
Mark
Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting
- Contribution to journal › Article
-
Mark
Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders
- Contribution to journal › Article
-
Mark
Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls
- Contribution to journal › Article
- 2022
-
Mark
Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
- Contribution to journal › Article
